CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie
  
CRISPR Therapeutics already has Casgevy on the market, but hopes its two in-vivo gene-editing cardiovascular drugs can reach a broader market.

More from Clinical Trials

More from Therapy Areas